Vivian LuiAssociate Professor

BSc.(Hons) in Biochemistry, CUHK; Ph.D.(Hons) in Molecular Pharmacology, USA

Telephone:  3943 5388

Email:  This email address is being protected from spambots. You need JavaScript enabled to view it.



 208A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK


  1. Integrated Cancer Genomic-Proteomic bioinformatics for therapeutics and translational research
  2. Functional genomics and platform development for druggable mutations and driver mutations in human oncogenesis
  3. Molecular mechanisms of mutation-based drug sensitivity for targeted therapies
  4. Mechanisms of viral-mediated oncogenesis in aerodigestive tract cancers and Nasopharyngeal cancer
  5. Patient-oriented pharmacogenomics
  1. Hedberg, M.L., Goh, G., Chiosea, S.I., Bauman, J.E., Freilino, M.L., Zeng, Y., Wang, L., Diergaarde, B.B., Gooding, W.E., Lui, V.W., Herbst, R.S., Lifton, R.P. and Grandis, J.R. (2016). The genetic landscape of head and neck cancer recurrence and metastasis. J. Clin. Investigation, 126(1), 169-180.
  2. Wen, Y., Li, H., Zeng, Y., Wen, W., Pendleton, K.P., Lui, V.W., Egloff, A.M. and Grandis, J.R. (2016). MAPK1(E322K) mutation increased head and neck suamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Oncotarget, 7(17), 23300-23311.
  3. Li, H., Wheeler, S., Park, Y., Ju, Z., Thomas, S.M., Fichera, M., Egloff, A.M., Lui. V.W., Duvvuri, U., Bauman, J.E., Mills, G.B. and Grandis, J.R. (2016). Proteomic characterization of head and neck cancer patient-derived xenografts. Mol. Cancer Res., 14(3), 278-286.
  4. Van Allen, E.M.*, Lui, V.W.*, Egloff, A.M., Goetz, E.M., Li, H., Johnson, J.T., Duvvuri, U., Bauman, J.E., Stransky, N., Zeng, Y., Gilbert, B.R., Pendleton, K.P., Wang, L., Chiosea, S., Sougnez, C., Wagle, N., Zhang, F., Du, Y., Close, D., Johnston, P.A., McKenna, A., Carter, S.L., Golub, T.R., Getz, G., Mills, G.B., Garraway, L.A. and Grandis, J.R. (2015). Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma. JAMA Oncology, 1(2), 238-244. *Co-first authorships.
  5. Du, Y., Peyser, N.D., Li, H., Lui, V.W., Xiao, X., Maciej, Fiefing, Chan, T.A. and Grandis, J.R. (2015). Loss-of-function PTPRD mutations lead to increased STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. PLos One, 10(8), e0135750.
  6. Yau, N.K., Fong, A.Y., Leung, H.F., Verhoeft, K.R., Lim, Q.Y., Lam, W.Y., Wong, I.C. and Lui, V.W. (2015). A Pan-Cancer review of ALK mutations: Implications for Carcinogenesis and Therapy. Current Cancer Drug Targets, 15(4), 327-336.
  7. Sen, M., Pollock, N.I., Black, J., DeGrave, K.A., Wheeler, S., Freilino, M.L., Joyce, S., Lui, V.W., Zeng, Y., Chiosea, S.I. and Grandis, J.R. (2015). JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth. Neoplasia, 17(3), 256-264.
  8. Wong, E.Y., Wong, S.C., Chan, C.M., Lam, E.K., Ho, L.Y., Lau, C.P., Au, T.C., Chan, A.K., Tsang, C.M., Tsao, S.W., Lui, V.W. and Chan, A.T. (2015). TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells. Oncology Letters, 9, 569-574. (*Corresponding author).
  9. Lui, V.W., Peyser, N.D., Ng, P.K., Hritz, J., Zeng, Y., Lu, Y., Li, H., Wang, L., Gilbert, B.R., General, I.J., Bahar, I., Ju, Z., Wang, Z., Pendleton, K.P., Xiao, X., Du, Y., Vries, J.K., Hammerman, P.S., Garraway, L.A., Mills, G.B., Johnson, D.E. and Grandis, J.R. (2014). Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc. Natl. Acad. Sci. U.S.A., 111(3), 1114-1119.
  10. Li, H., Wawrose, J.S., Gooding, W.E., Garraway, L.A., Lui, V.W., Peyser, N.D. and Grandis, J.R. (2014). Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: ARatioinal approach to preclinical model selection. Proc. Natl. Acad. Sci. U.S.A., 12(4), 571-582.
  11. Lei, Y., Lui, V.W., Grandis, J.R. and Egloff, A.M. (2014). Identification of Mutatioins in the PYRIN-Containing NLR Genes (NLRP) in Head and Neck Squamous Cell Cacinoma. PLos One, 9(1), e85619.
  12. Lui, V.W., Hedberg, M.L., Li, H., Vangara, B.S., Pendleton, K., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B.R., Freilino, M., Sauerwein, S., Peyser, N.D., Xiao, D., Diergaarde, B., Wang, L., Chiosea, S., Seethala, R., Johnson, J.T., Kim, S., Duvvuri, U., Ferris, R.L., Romkes, M., Nukui, T., Ng, K.S.P., Garraway, L.A., Hammerman, P.S., Mills, G.B., Grandis, J.R. (2013). Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discovery, 3(7), 761-769.
  13. Lui, V.W.*, Wong, E.Y., Ho, K., Ng, P.K., Lau, C.P., Tsui, S.K., Tsang, C.M., Tsao, S.W., Cheng, S.H., Ng, M.H., Ng, Y.K., Lam, E.K., Hong, B., Lo, K.W., Mok, T.S., Chan, A.T. and Mills, G.B. (2011). Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene, 30(9), 1127-1134.
  14. Lui, V.W.*, Yau, D.M.*, Cheung, C.S., Wong, S.C., Chan, A.K., Zhou, Q., Wong, E.Y., Lau, C.P., Lam, E.K., Hui, E.P., Hong, B., Hui, C.W., Chan, A.S., Ng, P.K., Ng, Y.K., Lo, K.W., Tsang, C.M., Tsui, S.K., Tsao, S.W. and Chan, A.T. (2011). FGF8b oncogene mediates proliferation and invasion of epstein-barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation. Oncogene, 30(13), 1518-30.
  15. Lai, S.Y., Koppikar, P., Thomas, S.M., Childs, E.E., Egloff, A.M., Seethala, R.R., Branstetter, B.F., Gooding, W.E., Muthukrishnan, A., Mountz, J.M., Lui, V.W., Shin, D.M., Agarwala, S.S., Johnson, R., Couture, L.A., Myers, E.N., Johnson, J.T., Mills, G., Argiris, A. and Grandis, J.R. (2009). Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. J. Clin. Oncol., 27(8):1235-1242.
  16. Zhang, Q., Thomas, S.M., Lui, V.W., Xi, S., Siegfried, J.M., Fan, H., Smithgall, T.E., Mills, G.B. and Grandis, J.R. (2006), Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc. Natl. Acad. Sci. U.S.A., 103(18), 6901-6906.
  17. Lui, V.W., Thomas, S.M., Zhang, Q., Wentzel, A.L., Siegfried, J.M., Li, J.Y. and Grandis, J.R. (2003). Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene, 22(40), 6183-93.
  18. Lango, M.N., Dyer, K.F., Lui, V.W., Gooding, W.E., Gubish, C., Siegfried, J.M. and Grandis, J.R. (2002). Gastrin-releasing peptide receptor-mediated autocrine growth in Squamous cell carcinoma of the head and neck. J. Natl. Cancer Inst., 94(5), 375-383.
  19. Lui, V.W., He, Y.K., Goyal, K. and Huang, L. (2001). Specific down-regulation fo HER-2 mediated by a chimeric U6 hammerhead ribozyme resulting in grwoth inhibition of human ovarian carcinoma. Molecular Therapy, 3(2), 169-177.
  20. Dou, Q.P. and Lui, V.W. (1995). Failure to dephosphorylate Retinoblastoma protein in drug-resistance cells. Cancer Research, 55(22),5222-5225.
Wen Y, Li H, Zeng Y, Wen W, Pendleton KP, Lui VW, Egloff AM, Grandis JR. MAPK1(E322K) mutation increased head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Oncotarget (2016; In Press) (IF: 6.359)